Document is current

Article History

Received: 27 January 2026

Accepted: 3 May 2026

First Online: 18 June 2026

Declarations

:

: Hiroji Iwata serves as a consultant to AstraZeneca, Chugai, Daiichi Sankyo, Eli Lilly, MSD, Pfizer, Gilead Sciences, and CMIC, received research grants from Chugai, AstraZeneca, MSD, Daiichi Sanklyo, and Novartis, and received honoraria for lectures from Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Gilead Sciences, and Myriad Genetics. Norikazu Masuda received research grants from Chugai, Eli Lilly, AstraZeneca, Pfizer, MSD, Daiichi Sanklyo, Eisai, Gilead Sciences, Novartis, and Oni-Pharma, received honoraria for lectures from Chugai, AstraZeneca, Eli Lilly, Daiichi Sankyo, Pfizer, Gilead Sciences, and Eisai, and served on the board of directors, unpaid, 2021–2025 at JCOG, board of directors, unpaid, 2007-current at JBCRG, board of directors, unpaid, 2021–2024 at Japanese Breast Cancer Society (JBCS), board of directors, unpaid, 2023–2025 at Japan Society of Clinical Oncology (JSCO), board of directors, unpaid, 2024-current at Japan Association of Breast Cancer Screening (JABCS), and board of directors, unpaid, 2025-current at KBCRN. Yutaka Yamamoto received research grants from Chugai, AstraZeneca, MSD, Daiichi Sanklyo, Novartis, Gilead Sciences, and Ono-Pharma, received honoraria for lectures from Chugai, AstraZeneca, Eli Lilly, Daiichi Sankyo, Pfizer, Gilead Sciences, Eisai, Kyowa-Kirin, Taiho, Takeda, Sysmex, Exact Science, Novartis, and MSD, received honoraria as advisory member from AstraZeneca, Pfizer, MSD, and Daiichi Sankyo, and served on the board of directors, unpaid, at JBCS and JBCRG. Tomomi Fujisawa has no conflict of interest. Tatsuya Toyama received honoraria for lectures from Chugai, Eli Lilly, Daiichi Sankyo, Pfizer, Taiho, MSD, and Novartis. Masahiro Kashiwaba has no conflict of interest. Shoichiro Ohtani received honoraria for lectures from Eli Lilly and Eisai. Naruto Taira received research grants from Eisai, Chugai, Daiichi Sanklyo, Kyowa Kirin, Taiho, and Eli Lilly, received honoraria for lectures from Chugai, Eli Lilly, Daiichi Sankyo, Pfizer, Takeda, MSD, Boehringer Ingelheim, Eisai, Kyowa-Kirin, and AstraZeneca, and served on the board of directors, unpaid, at JBCS. Takehiko Sakai has no conflict of interest. Yoshie Hasegawa has no conflict of interest. Rikiya Nakamura received honoraria for lectures from AstraZeneca, Kyowa-Kirin, and Eli Lilly. Takuhiro Yamaguchi serves as a consultant to Public Health Research Foundation, EPS Corporation, Japan Tobacco Inc, Ono-Pharma, Kowa Company, Ltd, Chugai, Daiichi-Sankyo, Eisai, Sonire, MSD, Boehringer Ingelheim, and Kakeshi Inc, received research grants from Kyowa-Kirin, Tsumura & Co, Daiichi Sankyo, Otsuka Pharma, Solasia Pharma, Cordis, and NTT DOCOMO, Inc, and received honoraria as advisory member from Incyte Biosciences Japan. Kentaro Sakamaki serves as a consultant to Ono-Pharma. Christy A Russell is an Employee of Exact Sciences. Naoko Sugiyama is an Employee of Exact Sciences.